公开(公告)号：US20240382539A1

公开(公告)日：2024-11-21

申请号：US18229592

申请日：2023-08-02

Applicant: Zhejiang University

Inventor： Haibo PAN ,  Laiming ZHANG ,  Shiguo CHEN ,  Xingqian YE ,  Donghong LIU ,  Tian DING

IPC: A61K35/747 ,  A61K31/366 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61P1/14

Abstract: The present disclosure provides use of an intestinal probiotic in preparation of a medicament that promotes metabolism of ellagic acid (EA) into urolithin A, a pharmaceutical composition and use thereof, and belongs to the technical field of biomedicine. In the present disclosure, probiotics capable of changing metabotypes of EA are selected from a plurality of probiotics. These probiotics alone or in combination can change an intestinal flora structure of a metabotype B and/or 0 population, thereby improving the efficiency of the metabolism of EA into urolithin A and increasing a yield of urolithin A. The present disclosure provides an intestinal probiotic for involving in and promoting the metabolism of EA into urolithin A, and provides a new idea for the treatment of diabetes, obesity, senescence, and diseases caused by central nervous system lesions and viral infection using urolithin A as an active pharmaceutical ingredient.

公开(公告)号：US20240382515A1

公开(公告)日：2024-11-21

申请号：US18214162

申请日：2023-06-26

Applicant: ZHEJIANG UNIVERSITY

Inventor： Shiguo CHEN ,  Laiming ZHANG ,  Haibo PAN ,  Xingqian YE ,  Donghong LIU ,  Tian DING

IPC: A61K31/715 ,  A61P3/00

Abstract: The present disclosure provides a water-soluble dietary fiber (WSDF), use thereof in preparation of a medicament that promotes metabolism of ellagic acid (EA) into urolithin A, and a pharmaceutical composition, and belongs to the technical field of biological pharmaceuticals. The WSDF provided by the present disclosure includes at least two components selected from the group consisting of gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, malto-oligosaccharide, pectin, β-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum, and inulin. In the present disclosure, compounding the foregoing different combinations of the WSDF and EA to feed mice may significantly increase the average urolithin A content in mouse feces. Visibly, the WSDF alone or in combination with EA may improve metabotypes of the EA in the body and increase urolithin A content, providing a new means for treating diabetes, obesity, senescence and central nervous system lesions.